Hydrazinide | 25415-88-7

• 分子结构分类: 无机化合物 - 均质非金属化合物 - 均质其他非金属化合物
• 英文名称: Hydrazinide
• 英文别名: aminoazanide
• CAS: 25415-88-7
• 化学式: H3N2-
• 分子量: 31.038
• InChiKey: XPXMKIXDFWLRAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  2
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  27
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  、 N-(cis-2-dimethylamino-cyclohexyl)-benzamide 、 Hydrazinide 、 盐酸 在 hydrochloride salt 、 Aminoazanide;hydrochloride 、 乙醚 作用下， 以 乙醚 为溶剂， 生成 cis-N-[2-(dimethylamino)cyclohexyl]benzamide hydrochloride
  参考文献：
  名称：

  Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants

  摘要：

  某些cis-N-(2-氨基-环戊基)苯甲酰胺的化合物，其化学式为##STR1## 其中m为0，n为2，r为烷基，R.sub.1和R.sub.2与氮原子结合表示为吡咯烷环，X和Y为氢原子或原子序数为9至35的卤素，例如，cis-3,4-二氯-N-甲基-n[2-(1-吡咯烷基)环己基]苯甲酰胺及其盐，已经发现具有中枢神经系统抗癫痫药物作用，例如抗惊厥药物特性，但几乎没有镇痛作用。

  公开号：

  US04801604A1

文献信息

• 1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones
  申请人：Abbott Laboratories

  公开号：US03939161A1

  公开（公告）日：1976-02-17

  Novel 1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidine-7(6H)-ones. The compounds exhibit central nervous system activity, particularly anti-convulsant and sedative activity, and also exhibit anti-inflammatory activity and gastric antisecretory activity.

  小说1,3-二甲基-1H-吡唑并[4,3-d]嘧啶-7(6H)-酮。这些化合物表现出中枢神经系统活性，特别是抗惊厥和镇静活性，并且表现出抗炎活性和胃抗分泌活性。
• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20040224955A1

  公开（公告）日：2004-11-11

  A compound of the formula I: 1 wherein: X is CH or N; Y is O or S; Z is OH, NH 2 , NMeR 3 , NHR 3 ; OR 3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR 7 or CR 5 , wherein R 5 is H, halogen, or (C 1-6 ) alkyl and R 7 is H or (C 1-6 alkyl), with the proviso that X and A are not both N; R 6 is H, halogen, (C 1-6 alkyl) or OR 7 , wherein R 7 is H or (C 1-6 alkyl); R 1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C 1-3 )alkyl, (C 2-6 )alkenyl, phenyl(C 2-6 )alkenyl, (C 3-6 )cycloalkyl, (C 1-6 )alkyl, CF 3 , 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C 2-6 )alkenyl and phenyl(C 1-3 )alkyl), alkenyl, cycloalkyl, (C 1-6 )alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-3 )alkyl, (C 6-10 )bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from 1 to 4 substituents; R 3 is selected from H, (C 1-6 )alkyl, (C 3-6 )cycloalkyl, (C 3-6 )cycloalkyl(C 1-6 )alkyl, (C 6-10 )aryl, (C 6-10 )aryl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-6 )cycloalkyl(C 2-6 )alkenyl, (C 6-10 )aryl(C 2-6 )alkenyl, N{(C 1-6 ) alkyl} 2 , NHCOO(C 1-6 )alkyl(C 6-10 )aryl, NHCO(C 6-10 )aryl, (C 1-6 )alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.

  化合物的公式I:1，其中：X为CH或N; Y为O或S; Z为OH，NH2，NMeR3，NHR3; OR3或1至4个杂原子从O，N和S中选择的5-或6成员杂环，该杂环可选地用1至4个取代基取代; A为N，COR7或CR5，其中R5为H，卤素或（C1-6）烷基，R7为H或（C1-6）烷基，但X和A不同时为N; R6为H，卤素，（C1-6）烷基或OR7，其中R7为H或（C1-6）烷基; R1选自由O，N和S选择的1至4个杂原子的5-或6成员杂环，苯基，苯基（C1-3）烷基，（C2-6）烯基，苯基（C2-6）烯基，（C3-6）环烷基，（C1-6）烷基，CF3，1至4个杂原子从O，N和S中选择的9-或10成员杂环，其中所述的杂环，苯基，苯基（C2-6）烯基和苯基（C1-3）烷基，烯基，环烷基，（C1-6）烷基和杂原子环都可选地用1至4个取代基取代; R2选自（C1-6）烷基，（C3-7）环烷基，（C3-7）环烷基（C1-3）烷基，（C6-10）双环烷基，金刚烷基，苯基和吡啶基，所有这些都可选地用1至4个取代基取代; R3选自H，（C1-6）烷基，（C3-6）环烷基，（C3-6）环烷基（C1-6）烷基，（C6-10）芳基，（C6-10）芳基（C1-6）烷基，（C2-6）烯基，（C3-6）环烷基（C2-6）烯基，（C6-10）芳基（C2-6）烯基，N{（C1-6）烷基}2，NHCOO（C1-6）烷基（C6-10）芳基，NHCO（C6-10）芳基，（C1-6）烷基-1至4个杂原子从O，N和S中选择的5-或10成员杂环，其中所述的烷基，环烷基，芳基，烯基和杂环都可选地用1至4个取代基取代; n为零或1;或其可检测的衍生物或盐。该发明的化合物可用作丙型肝炎病毒复制的抑制剂。该发明还提供一种治疗或预防丙型肝炎病毒感染的方法。
• Heterocyclic compounds useful as inhibitors of tyrosine kinases
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030207902A1

  公开（公告）日：2003-11-06

  Disclosed are novel compounds of formula (I): 1 wherein Ar 1 , X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

  本发明涉及一种新的化合物，其化学式为(I)：1，其中Ar1，X，Y，P，Q和Het的定义如下，这些化合物可用作某些蛋白质酪氨酸激酶的抑制剂，并因此可用于治疗由不适当细胞增殖引起的疾病，包括自身免疫性疾病、慢性炎症性疾病、过敏性疾病、移植排斥和癌症，以及由脑缺血引起的疾病，如中风。本发明还涉及包含这些化合物的制药组合物、制备这些化合物的方法以及在这些方法中有用的新型中间体化合物。
• Preparation of substituted and unsubstituted 2-carbamoyl nicotinic and
  申请人：American Cyanamid Company

  公开号：US04562257A1

  公开（公告）日：1985-12-31

  The invention provides a process for the preparation of substituted and unsubstituted 2-carbamoyl nicotinic and 3-quinolinecarboxylic acids.

  本发明提供了一种制备取代和未取代的2-氨基甲酰基烟酸和3-喹啉羧酸的方法。
• BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS
  申请人：Feng Yangbo

  公开号：US20110052562A1

  公开（公告）日：2011-03-03

  Compounds useful as Rho kinase inhibitors according to formula IA or IB: wherein A, B, D, E, R 1 , R 2 and Ar 1 are as defined herein, and any tautomer, salt, stereoisomer, hydrate, solvent, or prodrug thereof, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.

  提供公式IA或IB所示的有用的Rho激酶抑制剂化合物：其中A、B、D、E、R1、R2和Ar1的定义如本文所述，并提供任何互变异构体、盐、立体异构体、水合物、溶剂或前药，以及制药组合物、治疗方法和合成方法。